LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success (part 2)
Andernach and Montreal, June 25, 2025 (APA) -
About LTS Lohmann Therapie-Systeme AG We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches ("TTS") and Oral Thin Films ("OTF") as well as wearable drug delivery devices ("OBDS"). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches ("MAP") for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China. About Nualtis Nualtis is a specialty pharmaceutical company advancing innovative drug delivery technologies with a focus on oral thin film (OTF) pharmaceutical products. Nualtis’ superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm® and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. Nualtis’ innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions. Building on more than a decade of formulation and manufacturing expertise, Nualtis supports pharmaceutical partners in extending product lifecycles and accelerating development timelines. Headquartered in Montreal, the company offers a fully integrated platform that includes research and development, analytical services, regulatory support, and scalable manufacturing from lab to market. With a patient centered approach and a focus on execution excellence, Nualtis delivers smart solutions that meet real world therapeutic needs. Nualtis is a wholly owned subsidiary of atai Life Sciences. For more information, visit www.nualtis.com or connect with us on LinkedIn and X. For further information, please contact: LTS Lohmann Therapie-Systeme AG Dr Iris Schnitzler: iris.schnitzler@ltslohmann.com; https://www.ltslohmann.com Nualtis Tommy Kenny: tommy@nualtis.com www.nualtis.com Kiadó: APA/LTS Lohmann Therapie-Systeme AG ------------------------------------------------------------------- A Nemzeti Közleménytár oldalán található közlemények nem képezik az MTI hírkiadás részét, az MTI által szó szerint továbbított tartalomért minden esetben a közlemény beadója a felelős. A közlemények forrásmegjelöléssel (NKT) szabadon és korlátozás nélkül felhasználhatók. Az NKT szolgáltatással kapcsolatban további információt az nkt@dunamsz.hu elektronikus levelező címen kaphat.